

PACIFIC EDGE ANNUAL MEETING

Summary of meeting and results of the vote

Cancer diagnostics company, Pacific Edge (NZX: PEB), held its Annual Shareholder Meeting in Dunedin today, updating shareholders on its progress and Board and management priorities for FY19. The meeting provided strong support for the progress the Company was making.

The Company outlined that it continues to hold firm to its purpose of establishing Cxbladder as the world's leading molecular diagnostic technology for the detection and management of bladder cancer. The USA healthcare market, the world's largest, remains the primary opportunity and investment continues to be made into realising the significant potential.

Positive progress was made in FY18, with a number of commercial, reimbursement and coverage milestones resulting in growing adoption and sales of Cxbladder. New Zealand's healthcare practitioners are leading the way, with the majority of the large public healthcare providers (DHBs) now adopting Cxbladder into use in their clinical pathways.

The USA market remains the priority for FY19, with management focused on concluding commercial agreements with the large institutional accounts and payers it has targeted. "There is an increased focus on bringing on board large institutional healthcare organisations as customers and building on initial sales from the Veterans Administration. A continuing uplift in sales is expected" said Pacific Edge CEO David Darling.

In New Zealand the clinical validity and utility of Cxbladder is no longer questioned however additional clinical papers are expected to be published in peer reviewed clinical journals in FY19, upholding the strong performance of the tests providing greater evidence and reach to providers and payers globally.

The early success in Singapore is pleasing and management are working to transition healthcare organisations through User Programmes and add to the list of commercial customers in the region.

Chair of Pacific Edge, Chris Gallaher, said: "The EY-Parthenon ratified, addressable market size for Pacific Edge products in the USA is in excess of US\$1.2 billion. We have a fantastic suite of products, are making traction with our commercial strategy and are now starting to see some real movement in awareness and adoption of our technology. Our Company is uniquely placed to capitalise on the demand for better, more accurate, less invasive and more cost-effective diagnostics."

The CEO David Darling said "the Company achieved good commercial growth with a 29% increase in laboratory throughput to 14,400 tests, delivered 26% growth in revenue measured on a 'like-for-like' basis with last year and 6% growth in cash sales. Concluding that, there are very few young technology companies growing at this rate."

Shareholders voted in favour of all resolutions at the 2018 Annual Meeting.

Resolution	For	Against	Abstain
Re-election of Anatole Masfen	205,778,350 98.14%	3,906,815 1.86%	345,037
Authorise the Directors to fix the auditors' remuneration	209,414,030 99.84%	344,463 0.16%	271,709
Increase in aggregate Directors' fees to \$302,000 per annum	175,546,515 90.55%	18,311,814 9.45%	252,339

Copies of the annual meeting presentation and speeches are available on the company website www.pacifiedgedx.com.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacifiedge.co.nz www.pacifiedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

Refer to www.cxbladder.com for more information.